Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Boyd

Showing results (541-550 of 565) with videos related to

Pageof 57
Sort By:
Molecular Psychiatry|October 29, 2014
Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound AβE M Knight, H N Williams, A C Stevens, et al.
British Journal of Haematology|January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphomaLihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2020
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphomaTracy Murray Stewart, Daniel Von Hoff, Michael Fitzgerald, et al.
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Investigational New Drugs|June 29, 2016
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancerGiorgio Scagliotti, Jin Hyoung Kang, David Smith, et al.
Diabetes/Metabolism Research and Reviews|May 17, 2022
Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuriaClaire L Tonry, Raymond M Evans, Mark W Ruddock, et al.
British Journal of Cancer|April 23, 2005
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoL Pukac, P Kanakaraj, R Humphreys, et al.
British Journal of Pharmacology|July 1, 1996
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4B Hughes, D Howat, H Lisle, et al.
Cancer|December 24, 2015
Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer ProgramMark Lawler, Anna Gavin, Manuel Salto-Tellez, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 28, 2015
Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry MiceSu Xu, Yi Lun, Nastry Brignol, et al.
Pageof 57

Showing results (541-550 of 565) with videos related to

Sort By:
Pageof 57
Molecular Psychiatry|October 29, 2014
Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound AβE M Knight, H N Williams, A C Stevens, et al.
British Journal of Haematology|January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphomaLihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.
Cancer Chemotherapy and Pharmacology|November 20, 2020
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphomaTracy Murray Stewart, Daniel Von Hoff, Michael Fitzgerald, et al.
Blood Advances|January 4, 2018
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphomaSven de Vos, Nina D Wagner-Johnston, Steven E Coutre, et al.
Investigational New Drugs|June 29, 2016
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancerGiorgio Scagliotti, Jin Hyoung Kang, David Smith, et al.
Diabetes/Metabolism Research and Reviews|May 17, 2022
Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuriaClaire L Tonry, Raymond M Evans, Mark W Ruddock, et al.
British Journal of Cancer|April 23, 2005
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoL Pukac, P Kanakaraj, R Humphreys, et al.
British Journal of Pharmacology|July 1, 1996
The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4B Hughes, D Howat, H Lisle, et al.
Cancer|December 24, 2015
Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer ProgramMark Lawler, Anna Gavin, Manuel Salto-Tellez, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 28, 2015
Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry MiceSu Xu, Yi Lun, Nastry Brignol, et al.
Pageof 57